BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 17261624)

  • 1. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
    Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.
    Otsubo T; Maruyama K; Maesaki S; Miyazaki Y; Tanaka E; Takizawa T; Moribe K; Tomono K; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 1998 Jan; 42(1):40-4. PubMed ID: 9449258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
    Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis.
    Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A
    Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
    Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
    J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
    Manavathu EK; Cutright JL; Chandrasekar PH
    Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Prince RA; Chi J; Kontoyiannis DP
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.
    Mihara T; Kakeya H; Izumikawa K; Obata Y; Nishino T; Takazono T; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
    J Infect Chemother; 2014 Feb; 20(2):104-8. PubMed ID: 24462443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.
    Mouton JW; te Dorsthorst DT; Meis JF; Verweij PE
    Med Mycol; 2009 Dec; 47(8):802-7. PubMed ID: 19180360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
    Matot I; Pizov R
    Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
    Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
    Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis.
    Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A
    J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis.
    Cicogna CE; White MH; Bernard EM; Ishimura T; Sun M; Tong WP; Armstrong D
    Antimicrob Agents Chemother; 1997 Feb; 41(2):259-61. PubMed ID: 9021176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.
    Walsh TJ; Petraitis V; Petraitiene R; Field-Ridley A; Sutton D; Ghannoum M; Sein T; Schaufele R; Peter J; Bacher J; Casler H; Armstrong D; Espinel-Ingroff A; Rinaldi MG; Lyman CA
    J Infect Dis; 2003 Jul; 188(2):305-19. PubMed ID: 12854088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of aerosolized liposomal amphotericin B.
    Lambros MP; Bourne DW; Abbas SA; Johnson DL
    J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.